Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

43.07 -0.94 (-2.14%)
Official Closing Price Updated: 7:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) ↗
Lilly offers investors safety and growth. 
Via The Motley Fool
News headline image
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗
This biotech might have a bright future, but it'll need to survive against the incumbents to do so. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying ↗
The stock is known to soar on good news. 
Via The Motley Fool
News headline image
Here's Why Viking Therapeutics Stock Surged Higher in June ↗
Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug. 
Via The Motley Fool
News headline image
2 Top Growth Stocks to Buy Right Now Without Hesitation ↗
These stocks are no-brainer buys. 
Via The Motley Fool
Topics Economy
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now ↗
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly? ↗
Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead. 
Via The Motley Fool
News headline image
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? ↗
Novo Nordisk is no longer the front-runner, but it's not out of the running, either. 
Via The Motley Fool
News headline image
The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch ↗
These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Underrated Weight Loss Stocks to Buy and Hold ↗
They look well-positioned to grab a slice of the fast-growing anti-obesity market. 
Via The Motley Fool
News headline image
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk ↗
Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed. 
Via The Motley Fool
News headline image
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock? ↗
Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen. 
Via The Motley Fool
News headline image
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend ↗
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out. 
Via MarketBeat
Topics ETFs
News headline image
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock? ↗
These two healthcare leaders have a long history of competing against one another. 
Via The Motley Fool
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
All three could become highly prominent biotech companies within 10 years. 
Via The Motley Fool
News headline image
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow ↗
Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels. 
Via The Motley Fool
News headline image
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Going to $100? ↗
Viking stock is known for soaring after positive news. 
Via The Motley Fool
News headline image
Why Pfizer Stock Popped Today ↗
Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell. 
Via The Motley Fool
News headline image
80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? ↗
Novo Nordisk could maintain this latest early-mover advantage longer than you think. 
Via The Motley Fool
News headline image
Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? ↗
Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake. 
Via The Motley Fool
Topics Intellectual Property
News headline image
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors ↗
It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market. 
Via The Motley Fool
News headline image
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success ↗
Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better ↗
Can any company pose a serious challenge to Eli Lilly in the weight-loss market? 
Via The Motley Fool
News headline image
Here's What I Think Is Really Going on With Novo Nordisk Stock ↗
There is light at the end of the tunnel. 
Via The Motley Fool
News headline image
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals. 
Via The Motley Fool
News headline image
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage ↗
Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health. 
Via MarketBeat
News headline image
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗
An upcoming trial result could change how investors think about the weight-loss drug market. 
Via The Motley Fool
News headline image
Lexicon (LXRX) Q1 2026 Earnings Transcript ↗
Lexicon (LXRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.